Aethlon Medical Reports Reduced Net Loss, Advances Oncology Study to Final Cohort
AEMD sits 49% above its 52-week low of $1.36.
Summary
Aethlon Medical reported a substantial reduction in its net loss and operating expenses for fiscal year 2026, alongside significant clinical progress in its Australian oncology study and a $1.85 million capital raise.
Key Events · Earnings and Guidance · AEMD
-
Fiscal Year-End Financial Results
Reported a net loss of $7.2 million for fiscal year 2026, a significant reduction from $13.4 million in the prior year. Operating expenses also decreased by 21.9% to $7.3 million.
-
Clinical Trial Advancement
The Australian oncology study for the Hemopurifier advanced into its third and final dosing cohort, with the first participant in Cohort 3 successfully treated.
-
Capital Raise
Subsequent to fiscal year-end, the company raised approximately $1.85 million in net proceeds through its At-The-Market (ATM) program, bolstering its cash position.
-
Intellectual Property Expansion
Strengthened its IP portfolio with new patents issued in the U.S. and Europe covering Hemopurifier applications for coronavirus-related conditions, extending protection into the 2040s.
Analysis · AEMD · Industrial Applications And Services
Aethlon Medical's fiscal year-end report shows improved financial discipline with a significant reduction in net loss and operating expenses, which is crucial for a company that previously issued a going concern warning. The successful advancement of its Australian oncology study to the final cohort is a key clinical milestone, demonstrating progress in its core therapeutic development. While the company continues to rely on its At-The-Market program for capital, the $1.85 million raised provides additional runway, addressing immediate liquidity concerns, though the long-term financial stability remains a focus.
How filings like this one have moved
In the 30 days to Sep 16, 2026, 29.6% of the 1725 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.33%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AEMD was trading at $2.03 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $3.2M. The 52-week trading range was $1.36 to $27.40. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.